Radius Recycling 10-Q14 May 142014 Q1 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2014	14-May-14
Document and Entity Information	'	'
Entity Registrant Name	'Radius Health, Inc.	'
Entity Central Index Key	'0001428522	'
Document Type	'10-Q	'
Document Period End Date	31-Mar-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	385,664
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$29,558	$12,303
Prepaid expenses and other current assets	2,288	334
Total current assets	31,846	12,637
Property and equipment, net	60	76
Other assets	'	45
Total assets	31,906	12,758
Current liabilities:	'	'
Accounts payable	279	300
Accrued expenses and other current liabilities	19,131	22,007
Current portion of note payable, net of discount	10,161	13,005
Total current liabilities	29,571	35,312
Warrant liability	4,550	1,945
Commitments and contingencies	'	'
Stockholders' deficit:	'	'
Common stock, $.0001 par value; 100,000,000 shares authorized, 385,664 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively	0	0
Additional paid-in-capital	0	0
Accumulated deficit	-296,247	-277,301
Total stockholders' deficit	-296,247	-277,301
Total liabilities, convertible preferred stock and stockholders' deficit	31,906	12,758
Series B-2 Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	26,403	'
Stockholders' deficit:	'	'
Total stockholders' deficit	26,403	'
Series B Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	44,742	43,892
Stockholders' deficit:	'	'
Total stockholders' deficit	44,742	43,892
Series A-1 Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	80,497	78,737
Stockholders' deficit:	'	'
Total stockholders' deficit	80,497	78,737
Series A-2 Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	95,818	93,977
Stockholders' deficit:	'	'
Total stockholders' deficit	95,818	93,977
Series A-3 Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	12,499	12,232
Stockholders' deficit:	'	'
Total stockholders' deficit	12,499	12,232
Series A-4 Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	271	271
Stockholders' deficit:	'	'
Total stockholders' deficit	271	271
Series A-5 Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	525	525
Stockholders' deficit:	'	'
Total stockholders' deficit	525	525
Series A-6 Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	33,277	23,168
Stockholders' deficit:	'	'
Total stockholders' deficit	$33,277	$23,168

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	385,664	385,664
Common stock, shares outstanding	385,664	385,664
Series B-2 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	655,000	655,000
Preferred Stock, shares issued	448,060	0
Preferred Stock, shares outstanding	448,060	0
Series B Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	980,000	980,000
Preferred Stock, shares issued	701,235	701,235
Preferred Stock, shares outstanding	701,235	701,235
Series A-1 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	1,000,000	1,000,000
Preferred Stock, shares issued	939,612	939,612
Preferred Stock, shares outstanding	939,612	939,612
Series A-2 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	983,213	983,213
Preferred Stock, shares issued	983,208	983,208
Preferred Stock, shares outstanding	983,208	983,208
Series A-3 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	142,230	142,230
Preferred Stock, shares issued	142,227	142,227
Preferred Stock, shares outstanding	142,227	142,227
Series A-4 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	4,000	4,000
Preferred Stock, shares issued	3,998	3,998
Preferred Stock, shares outstanding	3,998	3,998
Series A-5 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	7,000	7,000
Preferred Stock, shares issued	6,443	6,443
Preferred Stock, shares outstanding	6,443	6,443
Series A-6 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	800,000	800,000
Preferred Stock, shares issued	682,958	496,111
Preferred Stock, shares outstanding	682,958	496,111

Condensed_Statements_of_Operat

Condensed Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
OPERATING EXPENSES:	'	'
Research and development	$9,717	$17,287
General and administrative	2,139	1,578
Loss from operations	-11,856	-18,865
OTHER (EXPENSE) INCOME:	'	'
Other (expense) income, net	-2,233	11,256
Interest income	2	2
Interest expense	-401	-698
NET LOSS	-14,488	-8,305
COMPREHENSIVE LOSS	-14,488	-8,305
LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS - BASIC AND DILUTED (Note 9):	($19,457)	($11,887)
LOSS PER SHARE:	'	'
Basic (in dollars per share)	($50.45)	($31.25)
Diluted (in dollars per share)	($50.45)	($31.25)
WEIGHTED AVERAGE SHARES:	'	'
Basic (in shares)	385,664	380,352
Diluted (in shares)	385,664	380,352

Statements_of_Convertible_Pref

Statements of Convertible Preferred Stock and Stockholders' Deficit (USD $)

Total

Common Stock

Additional Paid-In-Capital

Accumulated Deficit

Series B-2 Convertible Preferred Stock

Series B Convertible Preferred Stock

Series A-1 Convertible Preferred Stock

Series A-2 Convertible Preferred Stock

Series A-3 Convertible Preferred Stock

Series A-4 Convertible Preferred Stock

Series A-5 Convertible Preferred Stock

Series A-6 Convertible Preferred Stock

In Thousands, except Share data, unless otherwise specified

USD ($)

Balance at Dec. 31, 2013

($277,301)

$43,892

$78,737

$93,977

$12,232

$271

$525

$23,168

Balance (in shares) at Dec. 31, 2013

385,664

701,235

939,612

983,208

142,227

3,998

6,443

496,111

Increase (Decrease) in Stockholders' Equity

Net loss

-14,488

Issuance of preferred stock

26,152

10,109

Issuance of preferred stock (in shares)

448,060

186,847

Accretion of dividends on preferred stock

-4,969

-511

-4,458

251

850

1,760

1,841

267

Stock-based compensation expense

511

Balance at Mar. 31, 2014

($296,247)

$26,403

$44,742

$80,497

$95,818

$12,499

$271

$525

$33,277

Balance (in shares) at Mar. 31, 2014

385,664

448,060

701,235

939,612

983,208

142,227

3,998

6,443

682,958

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
CASH FLOWS USED IN OPERATING ACTIVITIES:	'	'
Net loss	($14,488)	($8,305)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	16	13
Stock-based compensation expense	511	334
Research and development expense settled in stock	2,717	3,570
Change in fair value of other current assets, warrant liability and other liability	2,233	-11,256
Non-cash interest	63	113
Changes in operating assets and liabilities:	'	'
Prepaid expenses and other current assets	-690	942
Accounts payable	-21	887
Accrued expenses and other current liabilities	2,453	6,423
Net cash used in operating activities	-7,206	-7,279
CASH FLOWS PROVIDED BY INVESTING ACTIVITIES:	'	'
Sales and maturities of marketable securities	'	4,000
Net cash provided by investing activities	'	4,000
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES:	'	'
Payments on note payable	-2,907	-1,969
Proceeds from the issuance of preferred stock, net	27,368	'
Net cash provided by financing activities	24,461	-1,969
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	17,255	-5,248
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	12,303	18,653
CASH AND CASH EQUIVALENTS AT END OF PERIOD	29,558	13,405
SUPPLEMENTAL DISCLOSURES:	'	'
Cash paid for interest	310	508
NON-CASH FINANCING ACTIVITIES:	'	'
Accretion of dividends on preferred stock	4,969	3,582
Fair value of series A-6 convertible preferred stock issued as settlement of liability	10,109	'
Fair value of warrants issued	$1,216	'

Organization

Organization	3 Months Ended
Organization	Mar. 31, 2014
Organization	'
Organization	'
	1. Organization

	Radius Health, Inc. (“Radius” or the “Company”), which was formerly known as MPM Acquisition Corp., is a science-driven biopharmaceutical company focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company’s lead product candidate is abaloparatide (BA058), a bone anabolic for the treatment of osteoporosis delivered via subcutaneous injection, which the Company refers to as Abaloparatide-SC. The Company is currently in Phase 3 development of Abaloparatide-SC and expects to announce top-line data from this study in late 2014. If the results are positive, the Company plans to submit a new drug application in the United States, and a marketing authorization application in Europe in mid-2015. The Company holds worldwide commercialization rights to Abaloparatide-SC, other than in Japan, and with a favorable regulatory outcome, anticipates its first commercial sales of Abaloparatide-SC will take place in 2016. The Company is leveraging its investment in Abaloparatide-SC to develop Abaloparatide-TD. The Company expects this line extension will provide improved patient convenience by enabling administration of abaloparatide through a short-wear-time transdermal patch. The Company has recently completed a successful Phase 2 proof of concept study of Abaloparatide-TD.

	The Company’s current clinical product portfolio also includes a novel oral agent, RAD1901, a selective estrogen receptor down-regulator/degrader (“SERD”). The Company is developing RAD1901 at higher doses, for the treatment of breast cancer brain metastases (“BCBM”). At lower doses RAD1901 acts as a selective estrogen-receptor modulator (“SERM”). Low-dose RAD1901 has shown efficacy for the treatment of vasomotor symptoms such as hot flashes in a successful Phase 2 clinical trial. In 2014, the Company expects to commence a Phase 1 clinical trial to evaluate RAD1901 for the treatment of BCBM.

	Pursuant to an Agreement and Plan of Merger (the “Merger Agreement” or the “Merger”) entered into in April 2011 by and among the Company (a public-reporting, Form 10 shell company at the time), RHI Merger Corp., a Delaware corporation and wholly owned subsidiary of the Company (“MergerCo”), and Radius Health, Inc., a privately-held Delaware corporation (“Former Operating Company”), MergerCo merged with and into the Former Operating Company, with the Former Operating Company remaining as the surviving entity and a wholly-owned subsidiary of the Company. This transaction is herein referred to as the “Merger”. The Merger was effective as of May 17, 2011, upon the filing of a certificate of merger with the Delaware Secretary of State. Following the Merger on May 17, 2011, the Company’s Board of Directors approved a transaction pursuant to which the Former Operating Company merged with and into the Company, leaving the Company as the surviving corporation (the “Short-Form Merger”). As part of the Short-Form Merger, the Company, then named MPM Acquisition Corp., changed its name to Radius Health, Inc. and assumed the operations of the Former Operating Company.

	The Company is subject to the risks associated with emerging companies with a limited operating history, including dependence on key individuals, a developing business model, market acceptance of the Company’s product candidates, competition for its product candidates, and the continued ability to obtain adequate financing to fund the Company’s future operations. The Company has incurred losses and expects to continue to incur additional losses for the foreseeable future. As of March 31, 2014, the Company had an accumulated deficit of $296.2 million and believes that its existing cash and cash equivalents at March 31, 2014, will be sufficient to fund its operations into the third quarter of 2014. Accordingly, the Company expects to pursue additional financing opportunities to address its capital needs, including the completion of a private placement or public offering and other strategic financing alternatives that could include, but are not limited to, partnering or other collaboration agreements. However, there is no guarantee that any of these financing opportunities will be executed or executed on favorable terms, and some could be dilutive to existing stockholders. If the Company fails to obtain additional future capital, it may be unable to complete its planned preclinical and clinical trials and obtain approval of any product candidates from the U.S. Food and Drug Administration or other regulatory authorities. In addition, the Company could be forced to discontinue product development, reduce or forego sales and marketing efforts, forego attractive business opportunities or discontinue operations entirely.

Basis_of_Presentation_and_Sign

Basis of Presentation and Significant Accounting Policies	3 Months Ended
Basis of Presentation and Significant Accounting Policies	Mar. 31, 2014
Basis of Presentation and Significant Accounting Policies	'
Basis of Presentation and Significant Accounting Policies	'
	2. Basis of Presentation and Significant Accounting Policies

	Basis of Presentation—The accompanying unaudited condensed financial statements and the related disclosures of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included.

	When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the three months ended March 31, 2014 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2014. Subsequent events have been evaluated up to the date of issuance of these financials. For further information, refer to the financial statements and footnotes included in the Company’s audited financial statements for the year ended December 31, 2013 included in the Company’s Annual Report on Form 10-K/A, as filed with the Securities and Exchange Commission on April 3, 2014.

	Significant Accounting Policies—The significant accounting policies identified in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2013 relate to research and development costs, stock-based compensation, fair value measures, property and equipment, license agreements, impairment of long-lived assets and income taxes. There were no changes to significant accounting policies during the three months ended March 31, 2014.

	Reverse Stock Split— On April 24, 2014, the Company effected a reverse stock split of the Company’s common stock at a ratio of one-for-2.28 of all of the outstanding shares of common stock. The number of authorized shares of the Company’s common stock and the par value did not change. Pursuant to the stock split, every 2.28 shares of the Company’s issued and outstanding common stock were automatically combined into one issued and outstanding share of the Company’s common stock. All shares and per share amounts in the condensed financial statements and accompanying notes have been retroactively adjusted to give effect to the reverse stock split.

	Recently Adopted Accounting Standards—In July 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”). ASU 2013-11 clarifies guidance and eliminates diversity in practice on the presentation of unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists at the reporting date. The amendments under ASU 2013-11 were effective for interim and annual fiscal periods beginning after December 15, 2013, with early adoption permitted. The Company adopted ASU 2013-11 on January 1, 2014. Its adoption did not have a material impact on the Company’s results of operations, financial position, or cash flows.

	In December 2013, the FASB issued Accounting Standards Update No. 2013-12, Definition of a Public Business Entity (“ASU 2013-12”). ASU 2013-12 amends the Master Glossary of the FASB Accounting Standards Codification to include one definition of public business entity for future use in GAAP. ASU 2013-12 does not affect existing requirements but will be used in considering the scope of new financial guidance and will identify whether the guidance does or does not apply to public business entities. The Company adopted ASU 2013-12 on January 1, 2014. Its adoption did not have a material impact on the Company’s results of operations, financial position or cash flows.

Accrued_Expenses_and_Other_Cur

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2014
Accrued Expenses and Other Current Liabilities	'
Accrued Expenses and Other Current Liabilities	'
	3. Accrued Expenses and Other Current Liabilities

	Accrued expenses and other current liabilities consist of the following (in thousands):

		March 31,		December 31,
		2014		2013
	Research costs - Nordic (1)	$	13,813	$	17,998
	Research costs - other	1,558		1,599
	Payroll and employee benefits	1,223		1,005
	Professional fees	1,533		426
	Vacation	75		69
	Interest on notes payable	880		852
	Other	49		58
	Total accrued expenses and other current liabilties	$	19,131	$	22,007

	(1) Includes amounts accrued ratably over the estimated per patient treatment period under the Nordic Work Statement NB-1 and Work Statement NB-3. Amounts do not include pass-through costs which are expensed as incurred or upon delivery. See note 7 for additional information.

Convertible_Preferred_Stock

Convertible Preferred Stock	3 Months Ended
Convertible Preferred Stock	Mar. 31, 2014
Convertible Preferred Stock	'
Convertible Preferred Stock	'
	4. Convertible Preferred Stock

	On February 14, 2014, the Company entered into a Series B-2 Convertible Preferred Stock and Warrant Purchase Agreement (the “Series B-2 Purchase Agreement”), pursuant to which the Company was able to raise up to approximately $40.2 million through the issuance of (1) up to 655,000 shares of its Series B-2 convertible preferred stock (“Series B-2”) and (2) warrants to acquire up to 718,201 shares of its common stock with an exercise price of $14.004 per share. In February and March 2014, the Company consummated closings under the Series B-2 Purchase Agreement, whereby, in exchange for aggregate gross proceeds to the Company of approximately $27.5 million, the Company issued an aggregate of 448,060 shares of Series B-2 and warrants to purchase up to a total of 491,293 shares of its common stock.

	The rights, preferences, and privileges of the Series B convertible preferred stock (“Series B”), Series B-2 convertible preferred stock (“Series B-2”), the Series A-1 convertible preferred stock (“Series A-1”), Series A-2 convertible preferred stock (“Series A-2”), Series A-3 convertible preferred stock (“Series A-3”), Series A-4 convertible preferred stock (“Series A-4”), Series A-5 convertible preferred stock (“Series A-5”) and Series A-6 convertible preferred stock (“Series A-6”) (the Series A-1, Series A-2, Series A-3, Series A-4, Series A-5 and Series A-6, collectively, the “Series A Preferred Stock”) as of March 31, 2014, are set forth below, and reflect the reverse stock split of the Company’s common stock effected on April 24, 2014, as previously discussed.

	Conversion— Any holder of the Company’s preferred stock has the right, at any time or from time to time, to convert any or all of its shares of preferred stock into fully paid and non-assessable shares of the Company’s common stock for each share of preferred stock converted based upon the then in effect Conversion Price (“Conversion Feature”). If the Company issues or sells any shares of its Common Stock (as defined by the Company’s certificate of incorporation) or options to purchase or other rights to subscribe for such convertible or exchangeable securities, in each case other than Excluded Stock (as defined by the Company’s certificate of incorporation), for a consideration per share less than the then in effect conversion price (“Dilutive Issuance”) of the Company’s Series A-1, A-2, A-3, B, or B-2 preferred stock, respectively, the Conversion Price for such series in effect immediately prior to each such Dilutive Issuance shall automatically be reduced in accordance with the provisions set forth in the Certificate of Designations. Upon issuance of each series of the Company’s preferred stock, the respective Conversion Prices were greater than the fair value of the Company’s common stock at the respective commitment dates. Therefore, the Conversion Feature was not considered to be a beneficial conversion feature that would require the Company to record a deemed dividend on the preferred stock. Each holder of Series B and Series B-2 shares has the right, at their option at any time, to convert any such shares of preferred stock into such number of fully paid shares of common stock as is determined by dividing the original purchase price of $61.42 by the conversion price (“Series B Optional Conversion”). The conversion price of the Series B and Series B-2 as of March 31, 2014 was $14.004 per share (the “Series B Conversion Price”), which represents a conversion ratio of one share of Series B or Series B-2 into approximately 4.386 shares of common stock.

	Each holder of Series A-1, Series A-2 and Series A-3 has the right, at their option at any time, to convert any such shares of preferred stock into such number of fully paid shares of common stock as is determined by dividing the original purchase price of $81.42 by the conversion price (“Optional Conversion”). The original conversion price of the Series A-1, Series A-2 and Series A-3 was $18.564 per share (the “Conversion Price”), which represented a conversion ratio of one share of Series A-1, Series A-2 or Series A-3 into approximately 4.386 shares of common stock. The issuance of the Series B in April and May of 2013 and the Series B-2 in February and March of 2014 resulted in an adjustment to the Conversion Price of the Series A-1, Series A-2 and Series A-3 (the “Anti-Dilution Adjustment”). As a result of the Anti-Dilution Adjustment, the conversion price of each share of Series A-1, Series A-2 and Series A-3 was reduced to $16.970, which represents a conversion ratio of one share of Series A-1, Series A-2 or Series A-3 into approximately 4.798 shares of common stock. This reduction of the Conversion Price did not create a beneficial conversion feature that would require the Company to record a deemed dividend on the Series A-1, Series A-2 or Series A-3 preferred stock.

	Each holder of Series A-4, Series A-5 and Series A-6 has the right, at their option at any time, to convert any such shares of preferred stock into such number of fully paid shares of common stock as is determined by dividing the original purchase price of $81.42 by the conversion price. The Conversion Price of the Series A-4, Series A-5 and Series A-6 as of March 31, 2014 was $18.564 per share, which represents a conversion ratio of one share of Series A-4, Series A-5 or Series A-6 into approximately 4.386 shares of common stock.

	Upon an optional conversion, the holders of the converted Series B-2, Series B and Series A Preferred Stock are entitled to payment of all accrued, whether or not declared, but unpaid dividends in shares of the common stock of the Company at the then effective Conversion Price.

	Each share of the Series B, Series B-2 and Series A Preferred Stock is automatically convertible into fully paid and non-assessable shares of common stock at the applicable conversion price (as described above) in effect upon, in the case of the Series A and Series B Preferred Stock, upon (1) a vote of the holders of at least 70% of the outstanding shares of Series B, Series B-2, Series A-1, Series A-2 and Series A-3 to convert all shares of Series B, Series B-2 and Series A Preferred Stock or (2) the common stock becoming listed for trading on a national stock exchange, and in the case of the Series B-2 Preferred Stock, upon (1) a vote of the holders of at least 70% of the outstanding shares of Series B-2 to convert all shares of Series B-2 Preferred Stock, (2) the closing of a firm commitment underwritten public offering on or prior to June 30, 2014 or (3) after June 30, 2014, the common stock becoming listed for trading on a national stock exchange (“Special Mandatory Conversion”). Upon a Special Mandatory Conversion, all accrued, whether or not declared, but unpaid dividends shall be paid in cash or shares of common stock (calculated based on the then effective conversion price) at the discretion of the Company’s Board of Directors.

	In the event of a conversion upon the closing of a firm commitment underwritten public offering on or prior to June 30, 2014 in which the public offering price per share is less than the Series B-2 Conversion Price, then the Series B-2 Conversion Price will automatically be reduced to the price equal to the public offering price.

	Redemption— Unless redemption is waived by a requisite stockholder vote or consent, the shares of Series B, Series B-2 and Series A Preferred Stock are automatically redeemable upon an event of sale of the Company. The shares of Series B, Series B-2 and Series A Preferred Stock are not redeemable at the option of the holder.

	Dividends— Holders of shares of Series B and Series B-2 are entitled to receive dividends at a rate of 8% per annum, compounding annually, which accrue on a daily basis commencing on the date of issuance of the shares of Series B and Series B-2. Dividends are payable, as accrued, upon liquidation, event of sale, and conversion to common stock, as described above. The holders of shares of Series B and Series B-2 are also entitled to dividends declared or paid on any shares of common stock.

	Following payment in full of required dividends to the holders of Series B and Series B-2, holders of shares of Series A-1 are entitled to receive dividends at a rate of 8% per annum, compounding annually, which accrue on a daily basis commencing on the date of issuance of the shares of Series A-1. Dividends are payable, as accrued, upon liquidation, event of sale, and conversion to common stock, as described above. The holders of shares of Series A-1 are also entitled to dividends declared or paid on any shares of common stock.

	Following payment in full of required dividends to the holders of Series B, Series B-2 and Series A-1, holders of Series A-2 are entitled to receive dividends at a rate of 8% per annum, compounding annually, which accrue on a daily basis commencing on the date of issuance of the shares of Series A-2. Dividends are payable, as accrued, upon liquidation, event of sale, and conversion to common stock, as described above. The holders of shares of Series A-2 are also entitled to dividends declared or paid on any shares of common stock.

	Following payment in full of required dividends to the holders of Series B, Series B-2, Series A-1 and Series A-2, holders of Series A-3 are entitled to receive dividends at a rate of 8% per annum, compounding annually, which accrue on a daily basis commencing on the date of issuance of the shares of Series A-3. Dividends are payable, as accrued, upon liquidation, event of sale and conversion to common stock, as described above. The holders of shares of Series A-3 are also entitled to dividends declared or paid on any shares of common stock.

	Without regard to the payment of required dividends to the holders of Series B, Series B-2, Series A-1, Series A-2 and Series A-3, holders of Series A-5 are entitled to receive the Series A-5 Special Accruing Dividend (as defined in the Company’s certificate of incorporation) paid in shares of Series A-6 as described in note 7. Dividends are payable, as accrued, upon liquidation, event of sale and conversion to common stock, as described above. The holders of shares of Series A-5 are also entitled to dividends declared or paid on any shares of common stock.

	Following payment in full of required dividends to the holders of Series B, Series B-2, Series A-1, Series A-2, Series A-3 and Series A-5, holders of Series A-4 and Series A-6 are entitled to receive, when, if and as declared by the Board of Directors, dividends on any shares of Series A-4 Stock or Series A-6 Stock, as the case may be, out of funds legally available for that purpose, at a rate to be determined by the Board of Directors if and when they may so declare any dividend on the Series A-4 Stock or A-6 Stock, as the case may be. Dividends are payable, as accrued, upon liquidation, event of sale, and conversion to common stock, as described above. The holders of shares of Series A-4 and Series A-6 are also entitled to dividends declared or paid on any shares of common stock.

	Dividends on the Company’s preferred stock are payable, at the sole discretion of the Board of Directors, in cash or in shares of the Company’s common stock at the current market price of shares of common stock, when and if declared by the Board of Directors and upon liquidation or an event of sale. All accrued but unpaid dividends on Series B, Series B-2 and Series A Preferred Stock will be paid in cash or shares of common stock, at the then effective Conversion Price of shares of Series B, Series B-2 and Series A Preferred Stock, upon a Special Mandatory Conversion (as defined in the Company’s certificate of incorporation). Upon Optional Conversion, dividends are payable in shares of common stock at the then effective conversion price of shares of preferred stock.

	As of March 31, 2014, the Company had accrued dividends of $3.2 million, $0.3 million, $16.8 million, $19.8 million and $2.9 million on Series B, Series B-2, Series A-1, Series A-2 and Series A-3, respectively.

	Voting—The holders of Series B, Series B-2 and Series A Preferred Stock are entitled to vote together with the holders of the common stock as one class on an as-if converted basis. In addition, as long as the shares of Series A-1 are outstanding, the holders of Series A-1, voting as a separate class, have the right to elect two members of the Company’s Board of Directors.

	Liquidation— The shares of Series B and Series B-2 rank equally to other shares of Series B and Series B-2, and rank senior to the Series A-1 and all other classes of Series A Preferred Stock. The shares of Series A-1 rank senior to all other classes of Series A Preferred Stock. Series A-2 ranks junior to Series A-1 and senior to Series A-3, Series A-4, Series A-5 and Series A-6. Series A-3, Series A-5 and Series A-6 rank equally but junior to Series A-1 and Series A-2 and senior to Series A-4. Series A-4 ranks senior to the Company’s common stock.

	In the event of a liquidation, dissolution, or winding-up of the Company, the holders of Series B and Series B-2 are entitled to be paid first out of the assets available for distribution, before any payment is made to the Series A Preferred Stock. Payment to the holders of Series B shall consist of two (2) times the original purchase price of $61.42, plus all accrued but unpaid dividends. Payment to the holders of Series B-2 shall consist of one and a half (1.5) times the original purchase price of $61.42, plus all accrued but unpaid dividends. After such distribution to the holders of Series B and Series B-2, the holders of Series A-1 will be entitled to be paid out of the remaining assets available for distribution, before any payment is made to the Series A-2, Series A-3, Series A-4, Series A-5 and Series A-6. Payment to the holders of Series A-1 shall consist of the original purchase price of $81.42, plus all accrued but unpaid dividends. After the distribution to the holders of Series A-1, the holders of Series A-2 will be entitled to receive an amount per share equal to the original purchase price per share of $81.42, plus any accrued but unpaid dividends. After the distribution to the holders Series A-1 and Series A-2, the holders of Series A-3, Series A-5 and Series A-6, will be entitled to receive an amount per share equal to the original purchase price per share of $81.42, plus any accrued but unpaid or declared and unpaid dividends, as appropriate. After the distribution to the holders Series A-1, Series A-2, Series A-3, Series A-5 and Series A-6, the holders of Series A-4 will be entitled to receive an amount per share equal to the original purchase price per share of $81.42, plus any declared and unpaid dividends. If the assets of the Company are insufficient to pay the full preferential amounts to the holders of Series B, the assets will be distributed ratably among the holders of Series B in proportion to their aggregate liquidation preference amounts. If the assets of the Company are insufficient to pay the full preferential amounts to the holders of Series A-1, the assets will be distributed ratably among the holders of Series A-1 in proportion to their aggregate liquidation preference amounts. If the assets of the Company are insufficient to pay the full preferential amounts to the holders of Series A-2, the assets will be distributed ratably among the holders of Series A-2 in proportion to their aggregate liquidation preference amounts. If the assets of the Company are insufficient to pay the full preferential amounts to the holders of Series A-3, Series A-5 and Series A-6, the assets will be distributed ratably among the holders of Series A-3, Series A-5 and Series A-6 in proportion to their aggregate liquidation preference amounts. If the assets of the Company are insufficient to pay the full preferential amounts to the holders of Series A-4, the assets will be distributed ratably among the holders of Series A-4 in proportion to their aggregate liquidation preference amounts. After all liquidation preference payments have been made to the holders of the Series B, Series B-2 and Series A Preferred Stock, the holders of the Series B, Series B-2 and Series A-1, Series A-2 and Series A-3 shall participate in the distribution of the remaining assets with the holders of the Company’s common stock on an as-if converted basis.

	In the event of, and simultaneously with, the closing of an event of sale of the Company (as defined in the Company’s Amended Certificate of Incorporation), the Company shall redeem all of the shares of Series B, Series B-2 and Series A Preferred Stock then outstanding at the Special Liquidation Price, as defined. If the event of sale involves consideration other than cash, the Special Liquidation Price may be paid with such consideration having a value equal to the Special Liquidation Price. The Special Liquidation Price shall be equal to an amount per share, which would be received by each holder of the Preferred Stock if, in connection with the event of sale, all the consideration paid in exchange for the assets or the shares of capital stock of the Company was actually paid to and received by the Company, and the Company was immediately liquidated thereafter and its assets distributed pursuant to the liquidation terms above.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
Fair Value Measurements	Mar. 31, 2014
Fair Value Measurements	'
Fair Value Measurements	'
	5. Fair Value Measurements

	The Company determines the fair values of its financial instruments based upon the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Below are the three levels of inputs that may be used to measure fair value:

	· Level 1—Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
	· Level 2—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	· Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

	The following table summarizes the financial instruments measured at fair value on a recurring basis in the accompanying condensed balance sheets as of March 31, 2014 and December 31, 2013 (in thousands):

			March 31, 2014
			Level 1			Level 2		Level 3		Total

	Assets
	Cash and cash equivalents:
	Cash		$	1,887		$	—	$	—	$	1,887
	Money market funds (1)		27,671			—		—		27,671
	Stock asset (2)		—			—		1,220		1,220
			$	29,558		$	—	$	1,220	$	30,778

	Liabilities
	Warrant liability (2)		$	—		$	—	$	4,550	$	4,550
			$	—		$	—	$	4,550	$	4,550

			December 31, 2013
			Level 1			Level 2		Level 3		Total

	Assets
	Cash and cash equivalents:
	Cash		$	2,710		$	—	$	—	$	2,710
	Money market funds (1)		9,593			—		—		9,593
			$	12,303		$	—	$	—	$	12,303

	Liabilities
	Warrant liability (2)		$	—		$	—	$	1,945	$	1,945
	Stock liability (2)		—			—		5,328		5,328
			$	—		$	—	$	7,273	$	7,273

	(1) Fair value is based upon quoted market prices.
	(2) Fair value is determined using the probability-weighted expected return model (“PWERM”), as discussed below. Changes in the fair value of the Level 3 assets and liabilities are recorded as other (expense) income in the condensed statement of operations.

	The stock asset represents the prepaid balance and the stock liability represents the accrued balance of the research and development expense related to the stock dividends to be issued to Nordic Bioscience Clinical Development VII A/S (“Nordic”) in shares of Series A-6 (or in shares of common stock if the Company lists its common stock on a national exchange) for services rendered which is being recognized ratably over the estimated per patient treatment period under the three work statements executed with Nordic (the “Nordic Work Statements”) (see note 7). The fair value of the stock asset and stock liability is based upon the fair value of the Series A-6 as determined using PWERM, which considers the value of the Company’s various classes of preferred stock. The fair value of the Company’s various classes of preferred stock is determined through an analysis of the future values for equity assuming various future outcomes. Accordingly, share value is based upon the probability weighted present value of expected future net cash flows, considering each of the possible future events, discount rate as determined using the capital asset pricing model, as well as the rights and preferences of each share class. PWERM is complex as it requires numerous assumptions relating to potential future outcomes of equity. Accordingly, the valuation of the Company’s stock asset and stock liability is determined using Level 3 inputs.

	The warrant liability represents the liability for the warrants issued to the placement agent in connection with the Company’s Series A-1 financing, to the investors in the Series B financing in April and May 2013 and the Series B-2 financing in February and March 2014, and to the lenders in connection with the Company’s Loan and Security Agreement executed with Oxford Finance LLC and General Electric Capital Corporation in May 2011. The warrant liability is calculated using the Black-Scholes option pricing method. This method of valuation includes using inputs such as the fair value of the Company’s common stock or preferred stock, historical volatility, the term of the warrant and risk free interest rates. The fair value of the Company’s shares of common stock and preferred stock is estimated using PWERM, as described above. Accordingly, the valuation of the warrant liability is determined using Level 3 inputs.

	As noted above, the Company’s Level 3 fair value measurements related to its stock asset, stock liability, and warrant liability are based upon the fair value of the Company’s common stock and preferred stock. The following table provides quantitative information about the fair value measurement of the Company’s common stock and preferred stock, including significant unobservable inputs:

	Instrument		Valuation		Unobservable Input		Estimate
	Instrument		Technique		Unobservable Input		Estimate
	Preferred Stock		PWERM		· Time until future exit event (years)		· 0.2 — 0.3
					· Probability of Abaloparatide coming to market		· 65% — 75%
					· Discount rate		· 20% — 40%
					· Long-term revenue growth rate (1)		· 2% — 117%
					· Long-term pre-tax operating margin (2)		· 13% — 79%
					· Discount for lack of marketability		· 6% — 33%

			Market Comparable Companies		· Revenue multiple (3)		· 3.6 — 8.4

	(1) Estimated long-term revenue growth rate has the above range and an average of approximately 27% over 16 revenue years.
	(2) Estimated long-term pretax operating margin has the above range after achieving positive pretax operating margin and an average of approximately 68% for 17 years.
	(3) Represents amounts used when the Company has determined that market participants would use such multiples when valuing the Company’s preferred stock.

	As of March 31, 2014, the stock asset and warrant liability have fair values of $1.2 million and $4.6 million, respectively. Changes in the significant unobservable inputs used in the fair value measurements of the Company’s common stock and preferred stock in isolation would result in a significantly different fair value measurement of the stock asset, stock liability, and warrant liability. Generally, a change in the assumption used for the probability of successful development is accompanied by a directionally similar change in the assumption used for the long-term revenue growth rate and long-term pre-tax operating margin and estimated fair value measurement of the Company’s common stock and preferred stock.

The following table provides a roll-forward of the fair value of the assets, where fair value is determined using Level 3 inputs (in thousands):

Balance at December 31, 2013		$	—
Issuance of shares of Series A-6 - prepayment		1,220
Balance at March 31, 2014		$	1,220

The following table provides a roll-forward of the fair value of the liabilities, where fair value is determined using Level 3 inputs (in thousands):

Balance at December 31, 2013		$	7,273
Issuance of shares of Series A-6		(8,889		)
Additions — accrued shares of Series A-6		2,717
Additions — warrants		1,216
Change in fair value		2,233
Balance at March 31, 2014		$	4,550

Additions represent the value of the asset or liability for additional accrued shares of stock issuable to Nordic for services rendered in connection with the Company’s Phase 3 Clinical Trial of Abaloparatide-SC (see note 7), as well as the value of any new warrants issued during the period. The issuance of shares of Series A-6 represent the release of the quarterly stock dividends of Series A-6 accrued under the Nordic Work Statements as of March 31, 2014 (see note 7).

The fair value of the Company’s note payable is determined using current applicable rates for similar instruments as of the balance sheet date. The carrying value of the Company’s note payable approximated its fair value as of March 31, 2014, as the Company’s interest rate is near current market rates. The fair value of the Company’s notes payable was determined using Level 3 inputs.

License_Agreements

License Agreements	3 Months Ended
License Agreements	Mar. 31, 2014
License Agreements	'
License Agreements	'
	6. License Agreements

	On September 27, 2005, the Company entered into a license agreement (the “Ipsen Agreement”), as amended, with SCRAS S.A.S, a French corporation on behalf of itself and its affiliates (collectively, “Ipsen”). Under the Ipsen Agreement, Ipsen granted to the Company an exclusive right and license under certain Ipsen compound technology and related patents to research, develop, manufacture and commercialize certain compounds and related products in all countries, except Japan and (subject to certain co-marketing and co-promotion rights retained by Ipsen) France. With respect to France, if Ipsen exercises its co-marketing and co-promotion rights, then Ipsen may elect to receive a percentage of the aggregate revenue from the sale of products by both parties in France (subject to a mid-double digit percentage cap) and Ipsen shall bear a corresponding percentage of the costs and expenses incurred by both parties with respect to such marketing and promotion efforts in France; Ipsen shall also pay Radius a mid-single digit royalty on Ipsen’s allocable portion of aggregate revenue from the sale of products by both parties in France. Abaloparatide (the Company’s bone growth drug) is subject to the Ipsen Agreement. Ipsen also granted the Company an exclusive right and license under the Ipsen compound technology and related patents to make and have made compounds or product in Japan. Ipsen also granted the Company an exclusive right and license under certain Ipsen formulation technology and related patents solely for purposes of enabling the Company to develop, manufacture and commercialize compounds and products covered by the compound technology license in all countries, except Japan and (subject to certain co-marketing and co-promotion rights retained by Ipsen) France. In consideration for these licenses, the Company made a nonrefundable, non-creditable payment of $250,000 to Ipsen, which was expensed during 2005. The Ipsen Agreement provides for further payments in the range of €10.0 million to €36.0 million ($13.8 million to $50.0 million) to Ipsen upon the achievement of certain development and commercialization milestones specified in the Ipsen Agreement, and for the payment of fixed 5% royalties on net sales of any product by the Company or its sub-licensees on a country-by-country basis until the last to expire of the licensed patents or for a period of 10 years after the first commercial sale in such country of any product that includes the compound licensed from Ipsen or any analog thereof, whichever is longer.

	If the Company sublicenses the rights licensed from Ipsen, then the Company will also be required to pay Ipsen a percentage of certain payments received from such sublicensee (in lieu of milestone payments not achieved at the time of such sublicense). The applicable percentage is in the low double digit range. In addition, if the Company or its sub-licensees commercialize a product that includes a compound discovered by it based on or derived from confidential Ipsen know-how, it will be obligated to pay to Ipsen a fixed low single digit royalty on net sales of such product on a country-by-country basis until the last to expire of its patents that cover such product or for a period of 10 years after the first commercial sale of such product in such country, whichever is longer. In connection with the Ipsen Agreement, the Company recorded less than $0.1 million in costs during both the three months ended March 31, 2014 and 2013, which were incurred by Ipsen and charged to the Company for the manufacture of the clinical supply of the licensed compound.

Research_Agreements

Research Agreements	3 Months Ended
Research Agreements	Mar. 31, 2014
Research Agreements	'
Research Agreements	'
	7. Research Agreements

	Abaloparatide-SC Phase 3 Clinical Trial—On March 29, 2011, the Company and Nordic entered into a Clinical Trial Services Agreement, a Work Statement NB-1 (the “Work Statement NB-1”) under such Clinical Trial Services Agreement and a related Stock Issuance Agreement, as amended to date (the “Stock Issuance Agreement”). Pursuant to the Work Statement NB-1, Nordic is managing the Phase 3 Clinical Trial (the “Phase 3 Clinical Trial”) of Abaloparatide-SC and is being compensated for such services in a combination of cash and shares of stock.

	In December 2011, the Company entered into an amendment to the Work Statement NB-1(the “First Amendment”). Pursuant to the original terms of the Work Statement NB-1, the study was to be conducted in 10 countries at a specified number of sites within each country. The terms of the First Amendment (1) provided for two additional countries (the United States and India) in which the trial would be conducted, (2) specified a certain number of sites within each such additional country for the conduct of the study, and (3) amended various terms and provisions of the Work Statement NB-1 to reflect the addition of such countries and sites within the study’s parameters. Payments to be made by the Company to Nordic under the First Amendment are denominated in both euros and U.S. dollars and total up to €717,700 ($988,775) and $289,663, respectively, for the 15 additional study sites in India contemplated by the First Amendment and up to €1.2 million ($1.7 million) and $143,369, respectively, for the five additional study sites in the United States contemplated by the First Amendment.

	In June 2012, the Company entered into a second amendment to the Work Statement NB-1(the “Second Amendment”). Pursuant to the original terms of the Work Statement NB-1, as amended by the First Amendment, the study was to be conducted in 12 countries at a specified number of sites within each country. The terms of the Second Amendment (1) increased the overall number of sites by adding sites in Europe, Brazil and Argentina and removing other sites, (2) specified a certain number of sites within each country for the conduct of the study, and (3) amended various terms and provisions of the Work Statement NB-1 to reflect additional services to be provided at existing sites and the addition of the new study sites within the study’s parameters. The Second Amendment also provided that cash payments to Nordic under the Clinical Trial Services Agreement as well as the payment of shares of stock under the related Stock Issuance Agreement will each be reduced by an amount of €11,941 ($16,451) per subject for any subjects enrolled in India or the United States. Such reductions are applied in pro rata monthly installments. Payments to be made by the Company to Nordic under the Second Amendment in connection with the additional services provided at existing sites and the conduct of the study at the new study sites are denominated in both euros and U.S. dollars and total of up to €3.7 million ($5.1 million) and $205,540, respectively.

	In March 2014, the Company entered into a fourth amendment to the Work Statement NB-1 (the “Fourth Amendment”). Pursuant to the terms of the Fourth Amendment, the Company agreed to pay to Nordic an additional performance incentive, or a Performance Incentive Payment, of $500,000 for every 50 patients that, subsequent to March 28, 2014, complete all end-of-study procedures, up to a maximum aggregate amount of additional payments equal to $5.0 million. Any Performance Incentive Payment will be paid in cash in the event an underwritten initial public offering of shares of the Company’s common stock (“IPO”) is consummated prior to May 31, 2014. Should an IPO not be consummated by the Company prior to May 31, 2014, any Performance Incentive Payments will be paid instead through the issuance to Nordic of shares of the Company’s capital stock under the same model for equity-based compensation that is contemplated by the existing outstanding work statements under the Clinical Trial Services Agreement.

	Pursuant to the Work Statement NB-1, the Company is required to make certain per patient payments denominated in both euros and U.S. dollars for each patient enrolled in the Phase 3 Clinical Trial followed by monthly payments for the duration of the study and final payments in two equal euro-denominated installments and two equal U.S. dollar-denominated installments. Changes to the Clinical Trial schedule may alter the timing, but not the aggregate amounts of the payments.

	The Work Statement NB-1, as amended on December 9, 2011, June 18, 2012 and March 28, 2014, provides for a total of up to approximately €41.2 million ($56.7 million) of euro-denominated payments and a total of up to approximately $3.2 million of U.S. dollar-denominated payments over the course of the Phase 3 Clinical Trial, plus Performance Incentive Payments of up to $5.0 million. These payments may be adjusted based upon actual sites opened, work performed or number of patients enrolled.

	Pursuant to the Stock Issuance Agreement, Nordic agreed to purchase the equivalent of €371,864 of Series A-5 at $8.142 per share, and 64,430 shares of Series A-5 were sold to Nordic on May 17, 2011 for proceeds of $525,154. These shares were exchanged in the Merger for an aggregate of 6,443 shares of the Company’s Series A-5.

	The Stock Issuance Agreement provides that Nordic is entitled to receive quarterly stock dividends, payable in shares of Series A-6 or shares of common stock if the Company’s preferred stock has been converted in accordance with its amended certificate of incorporation, having an aggregate value, under the Work Statement NB-1, of up to €36.8 million ($50.7 million) (the “Nordic Accruing Dividend”). In the event Nordic sells the shares of Series A-5 or in the event the shares of Series A-5 are converted into common stock in accordance with the Company’s amended certificate of incorporation, this right to receive the Nordic Accruing Dividend will terminate, but a right to receive an equivalent number of shares of Series A-6 or common stock, as applicable, will remain with Nordic as a contractual right under the Stock Issuance Agreement.

	The Nordic Accruing Dividend related to the Phase 3 Clinical Trial is determined based upon the estimated period that will be required to complete the Phase 3 Clinical Trial. On the last business day of each calendar quarter (each, an “Accrual Date”), beginning with the quarter ended June 30, 2011, the Company has a liability, under the Work Statement NB-1, to issue shares of Series A-6 (or common stock, after the conversion of the Company’s preferred stock into common stock) to Nordic that is referred to as the “Applicable Quarterly Amount” and is equal to €36.8 million ($50.7 million) (subject to adjustment in accordance with the applicable provisions of the Second Amendment relating to consideration payable for patients enrolled in India and the U.S.) minus the aggregate value of any prior Nordic Accruing Dividend accrued divided by the number of calendar quarters it will take to complete the Phase 3 Clinical Trial. To calculate the aggregate number of shares due to Nordic in each calendar quarter, the Company converts the portion of €36.8 million ($50.7 million) to accrue in such calendar quarter into U.S. dollars using the simple average of the exchange rate for buying U.S. dollars with euros for all Mondays in such calendar quarter. The Company then calculates the aggregate number of shares to accrue in such calendar quarter by dividing the U.S. dollar equivalent of the Applicable Quarterly Amount, by the greater of (1) the fair market value of the Company’s common stock as of the applicable Accrual Date or (2) $81.42 and rounding down the resulting quotient to the nearest whole number. Such shares due to Nordic are to be issued when declared or paid by the Company’s Board of Directors, who are required to do so upon Nordic’s request, or upon an event of sale. In December 2013, Nordic requested that all 438,124 shares of Series A-6 accrued as of December 31, 2013 under Work Statement NB-1 be issued. Accordingly, the Company’s Board of Directors declared a dividend to Nordic of all 438,124 shares accrued under Work Statement NB-1 on December 31, 2013.

	On March 28, 2014, the Company entered into Amendment No. 2 to the Amended and Restated Stock Issuance Agreement entered into by the parties as of May 16, 2011 (the “Second Stock Issuance Agreement Amendment”), with Nordic. The Second Stock Issuance Agreement Amendment required that the Company’s Board of Directors declare, as soon as reasonably practical, a stock dividend of twenty nine (29) shares of its Series A-6 for each share of the Company’s outstanding Series A-5, all of which are held by Nordic, for a total of 186,847 shares of Series A-6, in full satisfaction of all stock dividends payable in 2014 under the terms of the Stock Issuance Agreement in relation to Work Statement NB-1 and Work Statement NB-3, excluding any Performance Incentive Payments payable in stock. In March 2014, Nordic requested that all 186,847 shares of Series A-6 be issued. Accordingly, the Company’s Board of Directors declared and issued a dividend to Nordic of all 186,847 shares on March 31, 2014. The Second Stock Issuance Agreement Amendment provides further that in the event an IPO occurs prior to May 31, 2014, any payments owed by the Company to Nordic in relation to Work Statement NB-1 and Work Statement NB-3 for all periods of time after 2014, excluding any Performance Incentive Payments, will be changed from the right to receive stock to the right to receive a total cash payment from the Company of $4.3 million payable in ten equal monthly installments of $430,000 beginning on March 31, 2015. The Second Stock Issuance Agreement Amendment also stipulates that all consideration to be paid to Nordic pursuant to the Stock Issuance Agreement at any time after the consummation of an IPO be payable in cash.

	Prior to the issuance of shares of stock to Nordic in satisfaction of the Nordic Accruing Dividend, the liability to issue shares of stock was being accounted for as a liability in the Company’s balance sheet, based upon the fair value of the Series A-6 as determined using PWERM. Changes in the fair value from the date of accrual to the date of issuance of the Series A-6 shares are recorded as a gain or loss in other (expense) income in the statement of operations.

	The Company recognizes research and development expense for the amounts due to Nordic under the Work Statement NB-1, First Amendment and Second Amendment ratably over the estimated per patient treatment period beginning upon enrollment in the Phase 3 Clinical Trial, or a twenty-month period. The Company recognizes research and development expense for the amounts due to Nordic under the Fourth Amendment on a per patient basis when the End-of-Study visit and all other required procedures are completed. The Company recorded $4.5 million and $9.1 million of research and development expense during the three months ended March 31, 2014 and 2013, respectively, for per patient costs incurred for patients that had enrolled in the Phase 3 Clinical Trial.

	As of March 31, 2014, the Company had (1) an asset of $0.3 million reflected in prepaid expenses and other current assets on the balance sheet resulting from services provided by Nordic, which were paid in the form of a stock dividend and (2) a liability of $12.5 million that is reflected in accrued expenses and other current liabilities on the balance sheet resulting from services provided by Nordic, which are payable in cash.

	Abaloparatide-SC Phase 3 Clinical Extension Study—In February 2013, the Company entered into a Work Statement NB-3 (the “Work Statement NB-3”) under the Clinical Trial Services Agreement and the related Stock Issuance Agreement. Pursuant to Work Statement NB-3, Nordic will perform an extension study to evaluate six months of standard-of-care osteoporosis management following the completion of the 18-month Abaloparatide-SC Phase 3 Clinical Trial (the “Extension Study”) and will be compensated for such services in a combination of cash and shares of stock. Under the terms of a Letter of Intent that the Company entered into with Nordic on October 22, 2012 setting forth the parties’ obligations to negotiate in good faith to enter into Work Statement NB-3, the Company was required to make an initial payment of €806,468 ($1.1 million).

	In March 2014, the Company entered into an amendment to the Work Statement NB-3 (the “NB-3 Amendment”). The NB-3 Amendment was effective as of February 28, 2014 and provides that Nordic will perform a Period 2 extension study (the “Second Extension”), to evaluate an additional eighteen months of standard-of-care osteoporosis management following the Period 1 extension of six months upon completion of the Phase 3 clinical trial of the Company’s Abaloparatide-SC product. Payments in cash to be made by the Company to Nordic under the NB-3 Amendment are denominated in both euros and U.S. dollars and total up to approximately €3.0 million ($4.1 million) and $527,740, respectively. In addition, the Company agreed to issue to Nordic shares of the Company’s series A-6 convertible preferred stock having a value of up to approximately €3.0 million ($4.1 million) and $527,740 as additional payment for the services to be provided under the NB-3 Amendment, with the issuance of such shares to be made pursuant to the terms of an Amendment No. 2, entered into by the Company with Nordic on March 28, 2014, to the Amended and Restated Stock Issuance Agreement entered into by the parties as of May 16, 2011.

	Payments in cash to be made to Nordic under the Work Statement NB-3, as amended by the NB-3 Amendment, are denominated in both euros and U.S. dollars and total up to €7.5 million ($10.3 million) and $1.1 million, respectively. In addition, the Company will issue to Nordic, shares of the Company’s Series A-6 having a value of up to €7.5 million ($10.3 million) and $0.8 million, as additional payment for services to be provided under the Work Statement NB-3 and the Services Agreement.

	The Stock Issuance Agreement provides that, beginning with the quarter ended March 31, 2013, Nordic was entitled to receive quarterly stock dividends in connection with services performed under the Work Statement NB-3, payable in shares of Series A-6 or shares of common stock if the Company’s preferred stock has been automatically converted into common stock in accordance with its amended certificate of incorporation, having an aggregate value of up to €7.5 million ($10.3 million) and $0.8 million. In the event Nordic sells the shares of Series A-5 or in the event the shares of Series A-5 are converted into common stock in accordance with the Company’s amended certificate of incorporation, this right to receive the Nordic Accruing Dividend will terminate, but a right to receive an equivalent number of shares of Series A-6 or common stock, as applicable, will remain with Nordic as a contractual right under the Stock Issuance Agreement.

	The Nordic Accruing Dividend related to the Extension Study is determined based upon the estimated period that will be required to complete the Extension Study. On each Accrual Date, beginning with the quarter ended March 31, 2013, the Company will recognize a liability to issue shares of Series A-6 to Nordic with an Applicable Quarterly Amount value equal to €7.5 million ($10.3 million) and $0.8 million minus the aggregate value of any previously accrued Nordic Accruing Dividend related to the Extension Study divided by the number of calendar quarters it will take to complete the Extension Study. The Company calculates the aggregate number of shares of Series A-6 to accrue in such calendar quarter by dividing such Applicable Quarterly Amount, by the greater of (1) the fair market value of the Company’s common stock as of the applicable Accrual Date or (2) $81.42 and rounding down the resulting quotient to the nearest whole number. Such shares due to Nordic are to be issued when declared or paid by the Company’s Board of Directors, who are required to do so upon Nordic’s request, or upon an event of sale. In December 2013, Nordic requested that all 25,772 shares of Series A-6 accrued as of December 31, 2013 under Work Statement NB-3 be issued. Accordingly, the Company’s Board of Directors declared a dividend to Nordic of all 25,772 shares of Series A-6 accrued under Work Statement NB-3 on December 31, 2013.

	On March 28, 2014, the Company entered into the Second Stock Issuance Agreement Amendment, with Nordic. The Second Stock Issuance Agreement Amendment required that the Company’s Board of Directors declare, as soon as reasonably practical, a stock dividend of twenty nine (29) shares of its Series A-6 for each share of the Company’s outstanding Series A-5, all of which are held by Nordic, for a total of 186,847 shares of Series A-6, in full satisfaction of all stock dividends payable in 2014 under the terms of the Stock Issuance Agreement in relation to Work Statement NB-1 and Work Statement NB-3, excluding any Performance Incentive Payments payable in stock. In March 2014, Nordic requested that all 186,847 shares of Series A-6 be issued. Accordingly, the Company’s Board of Directors declared a dividend to Nordic of all 186,847 shares on March 31, 2014. The Second Stock Issuance Agreement Amendment provides further that in the event an IPO occurs prior to May 31, 2014, any payments owed by the Company to Nordic in relation to Work Statement NB-1 and Work Statement NB-3 for all periods of time after 2014, excluding any Performance Incentive Payments, will be changed from the right to receive stock to the right to receive a total cash payment from the Company of $4.3 million payable in ten equal monthly installments of $430,000 beginning on March 31, 2015. The Second Stock Issuance Agreement Amendment also stipulates that all consideration to be paid to Nordic pursuant to the Stock Issuance Agreement at any time after the consummation of an IPO be payable in cash.

	Prior to the issuance of the shares of Series A-6 to Nordic in satisfaction of the Nordic Accruing Dividend, the liability to issue shares of stock was being accounted for as a liability in the Company’s balance sheet, based upon the fair value of the Series A-6 as determined using PWERM. Changes in the fair value from the date of accrual to the date of issuance of the Series A-6 shares are recorded as a gain or loss in other (expense) income in the statement of operations.

	On December 6, 2013, the Company entered into a Letter of Intent (the “Letter of Intent”) with Nordic, which provided that the Company and Nordic would continue to negotiate the definitive terms of the NB-3 Amendment, which provides for an additional 18 months of standard-of-care treatment for those patients enrolled in the Extension Study being performed under Work Statement NB-3. The NB-3 Amendment was executed on March 28, 2014 and provides for payment by the Company to Nordic of both cash and equity compensation in consideration of the services provided by Nordic, with the equity portion of such compensation to be made pursuant to an Amendment No. 2 to the Amended and Restated Stock Issuance Agreement entered into by the parties as of May 16, 2011. Pursuant to the Letter of Intent, the Company was required to make an initial payment of €222,573 ($0.3 million) and agreed to commence payment of the cash compensation due in consideration of the services being provided by Nordic under the Amendment.

	The Company recognizes research and development expense for the amounts due to Nordic under the Work Statement NB-3 and Amendment ratably over the estimated per patient treatment periods beginning upon enrollment, or over a nine-month and nineteen-month period, respectively. The Company recorded $2.5 million and $0.5 million of research and development expense during the three months ended March 31, 2014 and 2013, respectively, for per patient costs incurred for patients that had enrolled in the Extension Study and Second Extension.

	As of March 31, 2014, the Company had (1) an asset of $0.9 million reflected in prepaid expenses and other current assets on the balance sheet resulting from services provided by Nordic, which were paid in the form of a stock dividend and (2) a liability of $1.3 million that is reflected in accrued expenses and other current liabilities on the balance sheet resulting from services provided by Nordic, which are payable in cash.

	Abaloparatide-TD Phase 2 Clinical Trial—On July 26, 2012, the Company entered into a Letter of Intent (the “Phase 2 Letter of Intent”) with Nordic, which provided that the Company and Nordic would, subject to compliance by the Company with certain requirements of its Certificate of Incorporation and applicable securities laws, negotiate in good faith to enter into (1) a Work Statement NB-2 (the “Work Statement NB-2”), a draft of which is attached to the Phase 2 Letter of Intent, and (2) an amendment to the Amended and Restated Stock Issuance Agreement.

	In February 2013, the Company executed the final Work Statement NB-2 under the Clinical Trial Services Agreement and the related Stock Issuance Agreement. Pursuant to the Work Statement NB-2, Nordic would provide clinical trial services relating to the Phase 2 Clinical Trial and would be compensated for such services in a combination of cash and shares of stock. Payments in cash to be made by the Company to Nordic under the Work Statement NB-2 were denominated in both euros and U.S. dollars and totaled up to €3.6 million ($5.0 million) and $0.3 million, respectively. In addition, the Company would issue to Nordic shares of its Series A-6 stock having a value of up to $2.9 million, as additional payment for services to be provided under the Work Statement NB-2 and the Clinical Trial Services Agreement.

	As of December 31, 2013, 32,215 shares of Series A-6 were due to Nordic under Work Statement NB-2, or, after the automatic conversion into common stock of the Company’s preferred stock, 141,294 shares the Company’s common stock. In December 2013, Nordic requested that all 32,215 shares of Series A-6 accrued as of December 31, 2013 under Work Statement NB-2 be issued. Accordingly, the Company’s Board of Directors declared a dividend to Nordic of all 32,215 shares of Series A-6 accrued under Work Statement NB-2 on December 31, 2013, which constituted all shares of Series A-6 due under Work Statement NB-2.

	The Company recognized research and development expense for the amounts due to Nordic under the Work Statement NB-2 ratably over the estimated per patient treatment period beginning upon enrollment in the Phase 2 Clinical Trial, or a nine-month period. The Company recorded nil and $1.7 million of research and development expense during the three months ended March 31, 2014 and 2013, respectively, for per patient costs incurred for patients that had enrolled in the Phase 2 Clinical Trial. As of March 31, 2014, all obligations due to Nordic under Work Statement NB-2 had been paid.

	The Company is also responsible for certain pass-through costs in connection with the Phase 3 Clinical Trial, Extension Study and Phase 2 Clinical Trial. Pass through costs are expensed as incurred or upon delivery. The Company recognized research and development expense of $0.3 million and $1.1 million for pass-through costs during the three months ended March 31, 2014 and 2013, respectively.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
Stock-Based Compensation	Mar. 31, 2014
Stock-Based Compensation	'
Stock-Based Compensation	'
	8. Stock-Based Compensation

	A summary of stock option activity during the three months ended March 31, 2014 is as follows (in thousands, except for per share amounts):

				Weighted-
				Average		Weighted-
				Exercise		Average
				Price (in		Contractual	Aggregate
				dollars per		Life (in	Intrinsic
		Shares		share)		years)	Value
	Options outstanding at December 31, 2013	1,667		$	7.05
	Granted	1,144		7.8
	Exercised	—		—
	Forfeited	(116	)	9
	Options outstanding at March 31, 2014	2,695		$	7.28	8.08	$	6,607
	Options exercisable at March 31, 2014	1,142		$	6.31	6.41	$	3,916
	Options vested or expected to vest at March 31, 2014	2,608		$	7.26	8.04	$	6,456

	The weighted-average grant-date fair value per share of options granted during the three months ended March 31, 2014 was $4.61, and the total grant-date fair value of stock options that vested during the three months ended March 31, 2014 was approximately $0.4 million. As of March 31, 2014, there was approximately $5.1 million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately 3.4 years.

Net_Loss_Per_Share

Net Loss Per Share	3 Months Ended
Net Loss Per Share	Mar. 31, 2014
Net Loss Per Share	'
Net Loss Per Share	'
	9. Net Loss Per Share

	Basic and diluted net loss per share is calculated as follows (in thousands, except share and per share numbers):

		Three Months Ended
		March 31,
		2014			2013
	Numerator:
	Net loss	$	(14,488	)	$	(8,305	)
	Accretion of Preferred Stock	(4,969		)	(3,582		)
	Loss attributable to common stockholders - basic and diluted	$	(19,457	)	$	(11,887	)

	Denominator:
	Weighted-average number of common shares used in loss per share - basic and diluted	385,664			380,352

	Loss per share - basic and diluted	$	(50.45	)	$	(31.25	)

	The following potentially dilutive securities, prior to the use of the treasury stock method, have been excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive. For the three months ended March 31, 2014 and 2013, all of the Company’s classes of preferred stock, options to purchase common stock and warrants outstanding were assumed to be anti-dilutive as earnings attributable to common stockholders was in a loss position.

		Three Months Ended
		March 31,
		2014		2013
	Convertible preferred stock	7,628,051		6,204,903
	Options to purchase common stock	2,121,606		1,710,152
	Warrants	1,010,257		14,850

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2014
Commitments and Contingencies	'
Commitments and Contingencies	'
	10. Commitments and Contingencies

	The Company may be exposed, individually or in the aggregate, to certain claims or assessments in the ordinary course of business. In the opinion of management, the outcome of these matters is not likely to have any material effect on the financial position, results of operations, or cash flows of the Company.

Subsequent_Events

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2014
Subsequent Events	'
Subsequent Events	'
	11. Subsequent Events

	Reverse Stock Split— On April 24, 2014, the Company effected a reverse stock split of its common stock at a ratio of one-for-2.28 of all of the outstanding shares of common stock. The number of authorized shares of the Company’s common stock and the par value did not change. Pursuant to the stock split, every 2.28 shares of the Company’s issued and outstanding common stock were automatically combined into one issued and outstanding share of the Company’s common stock.

Basis_of_Presentation_and_Sign1

Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Basis of Presentation and Significant Accounting Policies	'
Recently Adopted Accounting Standards	'
	Recently Adopted Accounting Standards—In July 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”). ASU 2013-11 clarifies guidance and eliminates diversity in practice on the presentation of unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists at the reporting date. The amendments under ASU 2013-11 were effective for interim and annual fiscal periods beginning after December 15, 2013, with early adoption permitted. The Company adopted ASU 2013-11 on January 1, 2014. Its adoption did not have a material impact on the Company’s results of operations, financial position, or cash flows.

	In December 2013, the FASB issued Accounting Standards Update No. 2013-12, Definition of a Public Business Entity (“ASU 2013-12”). ASU 2013-12 amends the Master Glossary of the FASB Accounting Standards Codification to include one definition of public business entity for future use in GAAP. ASU 2013-12 does not affect existing requirements but will be used in considering the scope of new financial guidance and will identify whether the guidance does or does not apply to public business entities. The Company adopted ASU 2013-12 on January 1, 2014. Its adoption did not have a material impact on the Company’s results of operations, financial position or cash flows.

Accrued_Expenses_and_Other_Cur1

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2014
Accrued Expenses and Other Current Liabilities	'
Schedule of accrued expenses and other current liabilities	'
	Accrued expenses and other current liabilities consist of the following (in thousands):

		March 31,		December 31,
		2014		2013
	Research costs - Nordic (1)	$	13,813	$	17,998
	Research costs - other	1,558		1,599
	Payroll and employee benefits	1,223		1,005
	Professional fees	1,533		426
	Vacation	75		69
	Interest on notes payable	880		852
	Other	49		58
	Total accrued expenses and other current liabilties	$	19,131	$	22,007

	(1) Includes amounts accrued ratably over the estimated per patient treatment period under the Nordic Work Statement NB-1 and Work Statement NB-3. Amounts do not include pass-through costs which are expensed as incurred or upon delivery. See note 7 for additional information.

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
Fair Value Measurements (Tables)	Mar. 31, 2014
Fair Value Measurements	'
Summary of financial instruments measured at fair value on a recurring basis	'
	The following table summarizes the financial instruments measured at fair value on a recurring basis in the accompanying condensed balance sheets as of March 31, 2014 and December 31, 2013 (in thousands):

		March 31, 2014
		Level 1			Level 2		Level 3		Total

	Assets
	Cash and cash equivalents:
	Cash	$	1,887		$	—	$	—	$	1,887
	Money market funds (1)	27,671			—		—		27,671
	Stock asset (2)	—			—		1,220		1,220
		$	29,558		$	—	$	1,220	$	30,778

	Liabilities
	Warrant liability (2)	$	—		$	—	$	4,550	$	4,550
		$	—		$	—	$	4,550	$	4,550

		December 31, 2013
		Level 1			Level 2		Level 3		Total

	Assets
	Cash and cash equivalents:
	Cash	$	2,710		$	—	$	—	$	2,710
	Money market funds (1)	9,593			—		—		9,593
		$	12,303		$	—	$	—	$	12,303

	Liabilities
	Warrant liability (2)	$	—		$	—	$	1,945	$	1,945
	Stock liability (2)	—			—		5,328		5,328
		$	—		$	—	$	7,273	$	7,273

	(1) Fair value is based upon quoted market prices.
	(2) Fair value is determined using the probability-weighted expected return model (“PWERM”), as discussed below. Changes in the fair value of the Level 3 assets and liabilities are recorded as other (expense) income in the condensed statement of operations.

Schedule of quantitative information about the Company's Level 3 fair value measurements, including significant unobservable inputs	'


	Instrument	Valuation		Unobservable Input		Estimate
	Instrument	Technique		Unobservable Input		Estimate
	Preferred Stock	PWERM		· Time until future exit event (years)		· 0.2 — 0.3
				· Probability of Abaloparatide coming to market		· 65% — 75%
				· Discount rate		· 20% — 40%
				· Long-term revenue growth rate (1)		· 2% — 117%
				· Long-term pre-tax operating margin (2)		· 13% — 79%
				· Discount for lack of marketability		· 6% — 33%

		Market Comparable Companies		· Revenue multiple (3)		· 3.6 — 8.4

	(1) Estimated long-term revenue growth rate has the above range and an average of approximately 27% over 16 revenue years.
	(2) Estimated long-term pretax operating margin has the above range after achieving positive pretax operating margin and an average of approximately 68% for 17 years.
	(3) Represents amounts used when the Company has determined that market participants would use such multiples when valuing the Company’s preferred stock.

Roll-forward of fair value of assets determined by Level 3 inputs	'
	The following table provides a roll-forward of the fair value of the assets, where fair value is determined using Level 3 inputs (in thousands):

	Balance at December 31, 2013	$	—
	Issuance of shares of Series A-6 - prepayment	1,220
	Balance at March 31, 2014	$	1,220

Roll-forward of fair value of liabilities determined by Level 3 inputs	'
	The following table provides a roll-forward of the fair value of the liabilities, where fair value is determined using Level 3 inputs (in thousands):

	Balance at December 31, 2013	$	7,273
	Issuance of shares of Series A-6	(8,889		)
	Additions — accrued shares of Series A-6	2,717
	Additions — warrants	1,216
	Change in fair value	2,233
	Balance at March 31, 2014	$	4,550

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
Stock-Based Compensation (Tables)	Mar. 31, 2014
Stock-Based Compensation	'
Summary of stock option activity	'
	A summary of stock option activity during the three months ended March 31, 2014 is as follows (in thousands, except for per share amounts):

				Weighted-
				Average		Weighted-
				Exercise		Average
				Price (in		Contractual	Aggregate
				dollars per		Life (in	Intrinsic
		Shares		share)		years)	Value
	Options outstanding at December 31, 2013	1,667		$	7.05
	Granted	1,144		7.8
	Exercised	—		—
	Forfeited	(116	)	9
	Options outstanding at March 31, 2014	2,695		$	7.28	8.08	$	6,607
	Options exercisable at March 31, 2014	1,142		$	6.31	6.41	$	3,916
	Options vested or expected to vest at March 31, 2014	2,608		$	7.26	8.04	$	6,456

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	3 Months Ended
Net Loss Per Share (Tables)	Mar. 31, 2014
Net Loss Per Share	'
Schedule of basic and diluted net loss per share	'
	Basic and diluted net loss per share is calculated as follows (in thousands, except share and per share numbers):

		Three Months Ended
		March 31,
		2014			2013
	Numerator:
	Net loss	$	(14,488	)	$	(8,305	)
	Accretion of Preferred Stock	(4,969		)	(3,582		)
	Loss attributable to common stockholders - basic and diluted	$	(19,457	)	$	(11,887	)

	Denominator:
	Weighted-average number of common shares used in loss per share - basic and diluted	385,664			380,352

	Loss per share - basic and diluted	$	(50.45	)	$	(31.25	)
Schedule of potentially dilutive securities excluded from the computation of diluted weighted-average shares outstanding	'

		Three Months Ended
		March 31,
		2014		2013
	Convertible preferred stock	7,628,051		6,204,903
	Options to purchase common stock	2,121,606		1,710,152
	Warrants	1,010,257		14,850

Organization_Details

Organization (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Organization	'	'
Accumulated deficit	$296,247	$277,301

Basis_of_Presentation_and_Sign2

Basis of Presentation and Significant Accounting Policies (Details)	0 Months Ended
	Apr. 24, 2014
Basis of Presentation and Significant Accounting Policies	'
Reverse stock-split ratio	2.28

Accrued_Expenses_and_Other_Cur2

Accrued Expenses and Other Current Liabilities (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Accrued Expenses and Other Current Liabilities	'	'
Research costs - Nordic	$13,813	$17,998
Research costs - other	1,558	1,599
Payroll and employee benefits	1,223	1,005
Professional fees	1,533	426
Vacation	75	69
Interest on notes payable	880	852
Other	49	58
Total accrued expenses and other current liabilities	$19,131	$22,007

Convertible_Preferred_Stock_De

Convertible Preferred Stock (Details) (USD $)	2 Months Ended	3 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2014	Feb. 14, 2014	Dec. 31, 2013
	Mar. 31, 2014	item	Feb. 14, 2014	Dec. 31, 2013
Series B	'	'	'	'
Convertible Preferred Stock	'	'	'	'
Number of shares issued	701,235	701,235	'	701,235
Number of shares authorized	980,000	980,000	'	980,000
Purchase price per share of convertible preferred stock (in dollars per share)	$61.42	$61.42	'	'
Conversion price per share (in dollars per share)	$14.00	$14.00	'	'
Preferred Stock conversion ratio (in shares)	4.386	4.386	'	'
Dividend rate (as a percent)	'	8.00%	'	'
Accrued dividend	$3.20	$3.20	'	'
Number of times of original purchase price, which will be paid to the preferred stockholders	'	200.00%	'	'
Number of classes of stockholder voting rights, in the aggregate, for preferred stockholders, on an as-if converted basis, together with common stockholders	'	1	'	'
Series B \| Minimum	'	'	'	'
Convertible Preferred Stock	'	'	'	'
Percentage of outstanding shares holders vote required for conversion of all shares of preferred stock	70.00%	70.00%	'	'
Series B-2	'	'	'	'
Convertible Preferred Stock	'	'	'	'
Number of shares issued	448,060	448,060	'	0
Number of shares authorized	655,000	655,000	'	655,000
Exercise price of warrants (in dollars per unit)	'	'	$14.00	'
Proceeds from issuance of shares	27.5	'	'	'
Purchase price per share of convertible preferred stock (in dollars per share)	$61.42	$61.42	'	'
Conversion price per share (in dollars per share)	$14.00	$14.00	'	'
Preferred Stock conversion ratio (in shares)	4.386	4.386	'	'
Dividend rate (as a percent)	'	8.00%	'	'
Accrued dividend	0.3	0.3	'	'
Number of times of original purchase price, which will be paid to the preferred stockholders	'	150.00%	'	'
Number of classes of stockholder voting rights, in the aggregate, for preferred stockholders, on an as-if converted basis, together with common stockholders	'	1	'	'
Series B-2 \| Minimum	'	'	'	'
Convertible Preferred Stock	'	'	'	'
Percentage of outstanding shares holders vote required for conversion of all shares of preferred stock	70.00%	70.00%	'	'
Series B-2 \| Maximum	'	'	'	'
Convertible Preferred Stock	'	'	'	'
Amount to be raised	'	'	40.2	'
Number of shares authorized	'	'	655,000	'
Warrants issued for purchase of shares of common stock (in shares)	'	'	718,201	'
Warrants issued for purchase of shares of common stock (in shares)	491,293	491,293	'	'
Series A Convertible Preferred Stock	'	'	'	'
Convertible Preferred Stock	'	'	'	'
Number of classes of stockholder voting rights, in the aggregate, for preferred stockholders, on an as-if converted basis, together with common stockholders	'	1	'	'
Series A-1	'	'	'	'
Convertible Preferred Stock	'	'	'	'
Number of shares issued	939,612	939,612	'	939,612
Number of shares authorized	1,000,000	1,000,000	'	1,000,000
Purchase price per share of convertible preferred stock (in dollars per share)	$81.42	$81.42	'	'
Conversion price per share (in dollars per share)	$16.97	$16.97	'	'
Original conversion price per share (in dollars per share)	$18.56	$18.56	'	'
Original preferred stock conversion ratio (in shares)	4.386	4.386	'	'
Preferred Stock conversion ratio (in shares)	4.798	4.798	'	'
Accrued dividend	16.8	16.8	'	'
Members of the Company's Board of Directors that can be elected by preferred stockholders	2	2	'	'
Series A-1 \| After payment in full of required Series B and B-2 preferred dividends	'	'	'	'
Convertible Preferred Stock	'	'	'	'
Dividend rate (as a percent)	'	8.00%	'	'
Series A-1 \| Liquidation, dissolution, or winding-up, payments to preferred stockholders after distribution to Series B and Series B-2 preferred stockholders	'	'	'	'
Convertible Preferred Stock	'	'	'	'
Purchase price per share of convertible preferred stock (in dollars per share)	$81.42	$81.42	'	'
Series A-1 \| Minimum	'	'	'	'
Convertible Preferred Stock	'	'	'	'
Percentage of outstanding shares holders vote required for conversion of all shares of preferred stock	70.00%	70.00%	'	'
Series A-2	'	'	'	'
Convertible Preferred Stock	'	'	'	'
Number of shares issued	983,208	983,208	'	983,208
Number of shares authorized	983,213	983,213	'	983,213
Purchase price per share of convertible preferred stock (in dollars per share)	$81.42	$81.42	'	'
Conversion price per share (in dollars per share)	$16.97	$16.97	'	'
Original conversion price per share (in dollars per share)	$18.56	$18.56	'	'
Original preferred stock conversion ratio (in shares)	4.386	4.386	'	'
Preferred Stock conversion ratio (in shares)	4.798	4.798	'	'
Accrued dividend	19.8	19.8	'	'
Series A-2 \| After payment in full of required Series B, Series B-2 and A-1 preferred dividends	'	'	'	'
Convertible Preferred Stock	'	'	'	'
Dividend rate (as a percent)	'	8.00%	'	'
Series A-2 \| Liquidation, dissolution, or winding-up, payments to preferred stockholders after distribution to Series B, SeriesB-2 and Series A-1 preferred stockholders	'	'	'	'
Convertible Preferred Stock	'	'	'	'
Purchase price per share of convertible preferred stock (in dollars per share)	$81.42	$81.42	'	'
Series A-2 \| Minimum	'	'	'	'
Convertible Preferred Stock	'	'	'	'
Percentage of outstanding shares holders vote required for conversion of all shares of preferred stock	70.00%	70.00%	'	'
Series A-3	'	'	'	'
Convertible Preferred Stock	'	'	'	'
Number of shares issued	142,227	142,227	'	142,227
Number of shares authorized	142,230	142,230	'	142,230
Purchase price per share of convertible preferred stock (in dollars per share)	$81.42	$81.42	'	'
Conversion price per share (in dollars per share)	$16.97	$16.97	'	'
Original conversion price per share (in dollars per share)	$18.56	$18.56	'	'
Original preferred stock conversion ratio (in shares)	4.386	4.386	'	'
Preferred Stock conversion ratio (in shares)	4.798	4.798	'	'
Accrued dividend	$2.90	$2.90	'	'
Series A-3 \| After payment in full of required Series B, Series B-2, Series A-1 and A-2 preferred dividends	'	'	'	'
Convertible Preferred Stock	'	'	'	'
Dividend rate (as a percent)	'	8.00%	'	'
Series A-3 \| Liquidation, dissolution, or winding-up, payments to preferred stockholders after distribution to Series B, Series B-2, Series A-1 and Series A-2 preferred stockholders	'	'	'	'
Convertible Preferred Stock	'	'	'	'
Purchase price per share of convertible preferred stock (in dollars per share)	$81.42	$81.42	'	'
Series A-3 \| Minimum	'	'	'	'
Convertible Preferred Stock	'	'	'	'
Percentage of outstanding shares holders vote required for conversion of all shares of preferred stock	70.00%	70.00%	'	'
Series A-4	'	'	'	'
Convertible Preferred Stock	'	'	'	'
Number of shares issued	3,998	3,998	'	3,998
Number of shares authorized	4,000	4,000	'	4,000
Purchase price per share of convertible preferred stock (in dollars per share)	$81.42	$81.42	'	'
Conversion price per share (in dollars per share)	$18.56	$18.56	'	'
Preferred Stock conversion ratio (in shares)	4.386	4.386	'	'
Series A-4 \| Liquidation, dissolution, or winding-up, payments to preferred stockholders after distribution to Series B, Series B-2, Series A-1, Series A-2 , Series A-3, Series A-5 and Series A-6 preferred stockholders	'	'	'	'
Convertible Preferred Stock	'	'	'	'
Purchase price per share of convertible preferred stock (in dollars per share)	$81.42	$81.42	'	'
Series A-5	'	'	'	'
Convertible Preferred Stock	'	'	'	'
Number of shares issued	6,443	6,443	'	6,443
Number of shares authorized	7,000	7,000	'	7,000
Purchase price per share of convertible preferred stock (in dollars per share)	$81.42	$81.42	'	'
Conversion price per share (in dollars per share)	$18.56	$18.56	'	'
Preferred Stock conversion ratio (in shares)	4.386	4.386	'	'
Series A-5 \| Liquidation, dissolution, or winding-up, payments to preferred stockholders after distribution to Series B, Series B-2, Series A-1 and Series A-2 preferred stockholders	'	'	'	'
Convertible Preferred Stock	'	'	'	'
Purchase price per share of convertible preferred stock (in dollars per share)	$81.42	$81.42	'	'
Series A-6	'	'	'	'
Convertible Preferred Stock	'	'	'	'
Number of shares issued	682,958	682,958	'	496,111
Number of shares authorized	800,000	800,000	'	800,000
Purchase price per share of convertible preferred stock (in dollars per share)	$81.42	$81.42	'	'
Conversion price per share (in dollars per share)	$18.56	$18.56	'	'
Preferred Stock conversion ratio (in shares)	4.386	4.386	'	'
Series A-6 \| Liquidation, dissolution, or winding-up, payments to preferred stockholders after distribution to Series B, Series B-2, Series A-1 and Series A-2 preferred stockholders	'	'	'	'
Convertible Preferred Stock	'	'	'	'
Purchase price per share of convertible preferred stock (in dollars per share)	$81.42	$81.42	'	'

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
	item	Dec. 31, 2013
Liabilities	'	'
Warrant liability	$4,550	$1,945
Number of work statements executed with the Nordic Work Statements	3	'
Level 3	'	'
Liabilities	'	'
Warrant liability	4,600	'
Recurring basis \| Level 1	'	'
Assets	'	'
Cash	1,887	2,710
Money market funds	27,671	9,593
Assets fair value	29,558	12,303
Recurring basis \| Level 3	'	'
Assets	'	'
Stock asset	1,220	'
Assets fair value	1,220	'
Liabilities	'	'
Warrant liability	4,550	1,945
Stock liability	'	5,328
Total liabilities carried at fair value	4,550	7,273
Recurring basis \| Estimated Fair Value	'	'
Assets	'	'
Cash	1,887	2,710
Money market funds	27,671	9,593
Stock asset	1,220	'
Assets fair value	30,778	12,303
Liabilities	'	'
Warrant liability	4,550	1,945
Stock liability	'	5,328
Total liabilities carried at fair value	$4,550	$7,273

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 2) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014
			Significant unobservable inputs	Preferred Stock	Preferred Stock	Preferred Stock	Preferred Stock	Preferred Stock
				Significant unobservable inputs	Significant unobservable inputs	Significant unobservable inputs	Significant unobservable inputs	Significant unobservable inputs
				PWERM	PWERM	PWERM	Market Comparable Companies	Market Comparable Companies
				Minimum	Maximum	Average	Minimum	Maximum
Quantitative information about the Company's Level 3 fair value measurements	'	'	'	'	'	'	'	'
Time until future exit event	'	'	'	'2 months 12 days	'3 months 18 days	'	'	'
Probability of Abaloparatide coming to market	'	'	'	65.00%	75.00%	'	'	'
Discount rate (as a percent)	'	'	'	20.00%	40.00%	'	'	'
Long-term revenue growth rate under scenario one (as a percent)	'	'	'	2.00%	117.00%	27.00%	'	'
Long-term pretax operating margin under scenario one (as a percent)	'	'	'	13.00%	79.00%	68.00%	'	'
Discount for lack of marketability (as a percent)	'	'	'	6.00%	33.00%	'	'	'
Revenue multiple	'	'	'	'	'	'	3.6	8.4
Revenue years used in calculation of average estimated long-term revenue growth rate under scenario one	'	'	'	'	'	'16 years	'	'
Years used in calculation of average estimated long-term pretax operating margin under scenario one	'	'	'	'	'	'17 years	'	'
Stock asset	'	'	$1,200,000	'	'	'	'	'
Warrant liability	$4,550,000	$1,945,000	$4,600,000	'	'	'	'	'

Fair_Value_Measurements_Detail2

Fair Value Measurements (Details 3) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Roll-forward of the fair value of the assets, where fair value is determined by Level 3 inputs	'
Issuance of shares of Series A-6 - prepayment	$1,220
Balance at the end of the period	1,220
Roll-forward of the fair value of the liabilities, where fair value is determined by Level 3 inputs	'
Balance at the beginning of the period	7,273
Issuance of shares of Series A-6	-8,889
Additions - accrued shares of Series A-6	2,717
Additions - warrants	1,216
Change in fair value	2,233
Balance at the end of the period	$4,550

License_Agreements_Details

License Agreements (Details)	3 Months Ended				12 Months Ended	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2005	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014
	USD ($)	USD ($)	License agreement	License agreement	License agreement	License agreement	License agreement	License agreement	License agreement	License agreement
			Ipsen	Ipsen	Ipsen	Ipsen	Ipsen	Ipsen	Ipsen	Ipsen
			USD ($)	USD ($)	USD ($)	Minimum	Minimum	Maximum	Maximum	Sublicense Agreement
						USD ($)	EUR (€)	USD ($)	EUR (€)	Minimum
License Agreements	'	'	'	'	'	'	'	'	'	'
Nonrefundable, non-creditable payment	'	'	'	'	$250,000	'	'	'	'	'
Additional payments to be made upon achievement of certain development and commercialization milestones	'	'	'	'	'	13,800,000	10,000,000	50,000,000	36,000,000	'
Royalty rate (as a percent)	'	'	5.00%	'	'	'	'	'	'	'
Period after the date of the first commercial sale of the product for license expiration	'	'	'	'	'	'10 years	'10 years	'	'	'10 years
Amount recorded in research and development expense	$9,717,000	$17,287,000	$100,000	$100,000	'	'	'	'	'	'

Research_Agreements_Details

Research Agreements (Details)

3 Months Ended

1 Months Ended

0 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Feb. 28, 2013

Feb. 28, 2014

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2011

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Feb. 28, 2013

Dec. 31, 2011

Mar. 31, 2014

Jun. 30, 2012

Mar. 31, 2014

17-May-11

Mar. 29, 2011

17-May-11

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 06, 2013

Mar. 31, 2014

USD ($)

Series A-5

Series A-6

Stock Issuance Agreement

Clinical Trial Services Agreement

USD ($)

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-TD Phase 2 Clinical Trial

Abaloparatide-SC Phase 3 Extension Clinical Study

Pass-through costs

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-TD Phase 2 Clinical Trial

Abaloparatide-SC Phase 3 Extension Clinical Study

NB-3 Amendment

First Amendment

Second Amendment

Fourth Amendment

Stock Issuance Agreement

Letter of Intent

Nordic

Maximum

Nordic

USD ($)

item

USD ($)

Per patient costs for enrolled patients

Nordic

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-SC Phase 3 Extension Clinical Study

Abaloparatide-SC Phase 3 Clinical Trial

Nordic

Abaloparatide-SC Phase 3 Clinical Trial

Abaloparatide-TD Phase 2 Clinical Trial

Abaloparatide-SC Phase 3 Extension Clinical Study

Series A-6

USD ($)

EUR (€)

Maximum

Series A-6

USD ($)

Maximum

Nordic

item

United States

India

Per patient costs for enrolled patients

item

USD ($)

EUR (€)

Maximum

Nordic

Series A-6

Nordic

USD ($)

item

USD ($)

EUR (€)

Maximum

USD ($)

EUR (€)

Maximum

Series A-6

item

Maximum

item

Maximum

USD ($)

EUR (€)

USD ($)

Maximum

USD ($)

Series A-5

Series A-6

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

Maximum

USD ($)

EUR (€)

USD ($)

EUR (€)

item

USD ($)

item

USD ($)

EUR (€)

Former Operating Company

Maximum

Minimum

Maximum

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

Research Agreements

Number of countries where study was to be conducted

Number of additional countries where study will be conducted

Number of additional study sites

Final payments, number of euro-denominated installments

Final payments, number of U.S dollar-denominated installments

Amount of euro-denominated payments required over the course of Clinical Trial

$56,700,000

€ 41,200,000

$5,000,000

€ 3,600,000

$10,300,000

€ 7,500,000

$4,100,000

€ 3,000,000

$1,700,000

€ 1,200,000

$988,775

€ 717,700

$5,100,000

€ 3,700,000

Amount of U.S. dollar-denominated payments required over the course of Clinical Trial

3,200,000

300,000

1,100,000

527,740

143,369

289,663

205,540

Value of shares agreed to be purchased

371,864

Purchase price per share of convertible preferred stock (in dollars per share)

$81.42

$8.14

$81.42

Additional term provided for standard-of-care treatment

'18 months

Dividend declared (in shares)

186,847

438,124

32,215

25,772

Stock dividends declared

Number of shares issued

6,443

682,958

496,111

186,847

Payments owed to be changed from the right to receive stock to the right to receive cash payment, if an IPO occurs prior to May 31, 2014

4,300,000

Number of equal monthly installments for cash payments

Amount of equal monthly installments for cash payments

430,000

Shares sold

64,430

Proceeds from issuance of shares

525,154

Number of shares exchanged in the Merger

6,443

Aggregate value of quarterly stock dividends, payable in shares

2,900,000

4,100,000

3,000,000

50,700,000

36,800,000

10,300,000

7,500,000

Aggregate U.S. dollar value of quarterly stock dividends, payable in shares

527,740

800,000

Number of shares due to the counter party

32,215

Number of shares due to the counter party after conversion of stock

141,294

Amount reflected in accrued expenses and other current liabilities resulting from services payable in cash

1,300,000

12,500,000

Assets reflected in prepaid expenses and other current assets resulting from services which are payable in the form of a stock dividend

900,000

300,000

Amount of initial payments for Euro-denominated installments

300,000

222,573

1,100,000

806,468

Maximum aggregate amount of additional payments

5,000,000

Amount of additional performance incentive payable to every specified patient

500,000

Number of patients to whom additional performance incentive is payable

Period for which research and development expense is recognized

'20 months

'9 months

'19 months

Research and development expense

9,717,000

17,287,000

300,000

1,100,000

4,500,000

9,100,000

1,700,000

2,500,000

500,000

Reduction in amount of euro-denominated payments required over the course of clinical study

$16,451

€ 11,941

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (Stock option, USD $)	3 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014
Stock option	'
Summary of stock option activity - Shares	'
Options outstanding at the beginning of the period (in shares)	1,667
Granted (in shares)	1,144
Exercised (in shares)	0
Forfeited (in shares)	-116
Options outstanding at the end of the period (in shares)	2,695
Options exercisable at the end of the period (in shares)	1,142
Options vested and expected to vest at the end of the period (in shares)	2,608
Summary of stock option activity - Weighted-Average Exercise Price (in dollars per share)	'
Options outstanding at the beginning of the period (in dollars per share)	$7.05
Granted (in dollars per share)	$7.80
Exercised (in dollars per share)	$0
Forfeited (in dollars per share)	$9
Options outstanding at the end of the period (in dollars per share)	$7.28
Options exercisable at the end of the period (in dollars per share)	$6.31
Options vested and expected to vest at the end of the period (in dollars per share)	$7.26
Weighted-Average Contractual Life (In Years)	'
Options outstanding at the end of the period	'8 years 29 days
Options exercisable at the end of the period	'6 years 4 months 28 days
Options vested and expected to vest at the end of the period	'8 years 14 days
Aggregate Intrinsic Value	'
Options outstanding at the end of the period (in dollars)	$6,607,000
Options exercisable at the end of the period (in dollars)	3,916,000
Options vested and expected to vest at the end of the period (in dollars)	6,456,000
Additional disclosures	'
Weighted-average grant-date fair value (in dollars per share)	$4.61
Total grant date fair value of stock options vested	$400,000

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 2) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014
Summary of stock-based compensation expense	'
Total unrecognized compensation expense	$5.10
Weighted average period over which unrecognized compensation is expected to be recognized	'3 years 4 months 24 days

Net_Loss_Per_Share_Details

Net Loss Per Share (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Numerator:	'	'
Net loss	($14,488)	($8,305)
Accretion of Preferred Stock	-4,969	-3,582
Loss attributable to common stockholders - basic and diluted	($19,457)	($11,887)
Denominator:	'	'
Weighted-average number of common shares used in loss per share - basic and diluted	385,664	380,352
Loss per share - basic and diluted (in dollars per share)	($50.45)	($31.25)

Net_Loss_Per_Share_Details_2

Net Loss Per Share (Details 2)	3 Months Ended
Net Loss Per Share (Details 2)	Mar. 31, 2014	Mar. 31, 2013
Convertible preferred stock	'	'
Net Loss Per Share	'	'
Potentially dilutive securities, prior to the use of the treasury stock method, excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive	7,628,051	6,204,903
Options to purchase common stock	'	'
Net Loss Per Share	'	'
Potentially dilutive securities, prior to the use of the treasury stock method, excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive	2,121,606	1,710,152
Warrants	'	'
Net Loss Per Share	'	'
Potentially dilutive securities, prior to the use of the treasury stock method, excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive	1,010,257	14,850

Subsequent_Events_Details

Subsequent Events (Details)	0 Months Ended
Subsequent Events (Details)	Apr. 24, 2014
Subsequent Events	'
Reverse stock-split ratio	2.28
Subsequent Event	'
Subsequent Events	'
Reverse stock-split ratio	2.28